Sytheon Granted 2 New US Patents on Isosorbide Diesters for Treating Atopic Dermatitis, Seeking Exclusive Partner to Bring to Market
13 Dec 2023
PARSIPPANY, N.J., Dec. 13, 2023 /PRNewswire/ -- Sytheon is thrilled to announce that its new turnkey product for treating Atopic Dermatitis (eczema) has further patent protection – and is actively seeking an exclusive partner to bring it to the OTC dermatological market.
There is currently an unmet need for a sustainable, safe, and cost-effective product for those with mild to moderate Atopic Dermatitis (AD). Sytheon has a turnkey product, ActSES®, with solid science, patent protection, and clinical validation by UC-Davis, CA dermatologists – and a new clinical study on children underway.
Continue Reading
Post this
Preview
Source: PRNewswire
Sytheon is seeking an exclusive partnership to bring turnkey atopic dermatitis treatment product to market.
Market Opportunity for Atopic Dermatitis (AD)
Topical therapies are a mainstay treatment for AD, particularly for children or those with mild-to-moderate disease who may not qualify for systemic medications. The complexity of chronic AD is increased by the interplay of skin barrier dysfunction and immune dysregulation, resulting in the perpetuation of AD signs and symptoms.
ActSES®, a unique synergistic combination product of Isosorbide di-(linoleate/oleate) (Hydra Synol® IDL) + Isosorbide di-caprylate (Hydra Synol® DOI), has been developed by Sytheon to serve this unmet need. The effects of topically applied ActSES® are not limited to barrier repair but synergistically inhibit inflammatory cascades that amplify pruritus and cutaneous eruption.
For ActSES®, Sytheon has obtained two new US patents 11,753,414 (method) & 11,753,415 (composition), entitled "Composition and Methods for Treating Atopic Dermatitis." Sytheon has two earlier US Patents (10,597,402 & 11,312,725), which disclose "compositions and methods for restoring epidermal integrity and function and treating dermatological diseases."
Sytheon is actively looking for an exclusive partnership with the right organization to bring this turnkey product to the OTC dermatological market. To inquire, please send us a message here.
This news piece is also featured on SpecialChem and HAPPI.
About Sytheon
Visit our website: www.sytheonltd.com
SOURCE Sytheon Ltd.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.